Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders

  title={Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders},
  author={C. Scuderi and D. D. Filippis and T. Iuvone and A. Blasio and Antonio Steardo and G. Esposito},
  journal={Phytotherapy Research},
  • C. Scuderi, D. D. Filippis, +3 authors G. Esposito
  • Published 2009
  • Medicine
  • Phytotherapy Research
  • Cannabidiol (CBD) is the main non‐psychotropic component of the glandular hairs of Cannabis sativa. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, antiinflammatory and neuroprotective properties. However, it is well established that CBD produces its biological effects without exerting significant intrinsic activity upon cannabinoid receptors. For this reason, CBD lacks the unwanted psychotropic effects characteristic of marijuana derivatives, so… CONTINUE READING
    116 Citations
    Potential Effects of Cannabidiol as a Wake-Promoting Agent
    • 18
    • PDF
    Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.
    • 7
    • PDF
    Cannabidiol, neuroprotection and neuropsychiatric disorders.
    • 135
    • PDF
    annabidiol , neuroprotection and neuropsychiatric disorders
    • lline C. Camposa, Manoela V. Fogaç, Andreza B. Sonegoa, rancisco S. Guimarãesa
    • 2016
    • PDF
    Cannabidiol and epilepsy: Rationale and therapeutic potential.
    • 45
    From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?
    • 10
    • Highly Influenced
    • PDF
    Title : Basic neuroanatomy and neuropharmacology of cannabinoids
    • PDF


    Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.
    • 141
    • PDF
    Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
    • 268
    • PDF
    The anticonvulsant activity of cannabidiol and cannabinol.
    • 106
    Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
    • 462
    • PDF
    The Cannabinoids as Potential Antiepileptics
    • 111
    • PDF
    Open label evaluation of cannabidiol in dystonic movement disorders.
    • 124
    Cannabidiol monotherapy for treatment-resistant schizophrenia
    • 144
    Hypnoticlike effects of cannabidiol in the rat
    • J. Monti
    • Psychology, Medicine
    • Psychopharmacology
    • 2004
    • 53